

Date: 11<sup>th</sup> May, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Publication of Audited Financial Results.**

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March, 2024, published in Business Standard & Indian Express (English Edition) and Sandesh & Financial Express (Gujarati Edition) on 11<sup>th</sup> May, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**




**Manisha Saraf**  
**Company Secretary**

Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123





**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123  
 Regd. Office: Alembic Road, Vadodara - 390 003  
 Tel: 0265-6637300  
 Email: apl.investors@alembic.co.in  
 Website: www.alembicpharmaceuticals.com

**Extract of statement of consolidated audited financial results for the quarter and financial year ended 31<sup>st</sup> March, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Total Income from Operations	1,516.98	1,406.45	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period after tax attributable to shareholders of the Company (after Exceptional and/ or Extraordinary items)	178.21	152.60	615.82
Total Comprehensive Income for the period	166.70	151.42	604.96
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.07	7.76	31.33

**Notes:**

1: Standalone details	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Income from Operations	1,474.55	1,307.12	5,874.06
Profit Before Tax	216.16	84.01	704.23
Profit After Tax	201.87	130.54	666.48

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited  
 Sd/-

Place: Vadodara  
 Date: 9<sup>th</sup> May, 2024

Chirayu Amin  
 Chairman and CEO

Note: The above results were also published yesterday. However, inadvertently, the details for the financial year ended 31<sup>st</sup> March, 2024 was missed out and hence this publication.





**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123  
Regd. Office: Alembic Road, Vadodara - 390 003  
Tel: 0265-6637300  
Email: apl.investors@alembic.co.in  
Website: www.alembicpharmaceuticals.com

**Extract of statement of consolidated audited financial results for the quarter and financial year ended 31<sup>st</sup> March, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Total Income from Operations	1,516.98	1,406.45	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period after tax attributable to shareholders of the Company (after Exceptional and/ or Extraordinary items)	178.21	152.60	615.82
Total Comprehensive Income for the period	166.70	151.42	604.98
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.07	7.76	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Income from Operations	1,474.55	1,307.12	5,874.06
Profit Before Tax	216.16	84.01	704.23
Profit After Tax	201.87	130.54	666.48

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited

Sd/-

Place: Vadodara  
Date: 9<sup>th</sup> May, 2024

Chirayu Amin  
Chairman and CEO

Note: The above results were also published yesterday. However, inadvertently, the details for the financial year ended 31<sup>st</sup> March, 2024 was missed out and hence this publication.





**ALEMBIC PHARMACEUTICALS LIMITED**  
 CIN: L24230GJ2010PLC061123  
 Regd. Office: Alembic Road, Vadodara - 390 003  
 Tel: 0265-6637300  
 Email: apl.investors@alembic.co.in  
 Website: www.alembicpharmaceuticals.com

**Extract of statement of consolidated audited financial results for the quarter and financial year ended 31<sup>st</sup> March, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Total Income from Operations	1,516.98	1,406.45	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary Items)	182.85	116.17	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period after tax attributable to shareholders of the Company (after Exceptional and/ or Extraordinary Items)	178.21	152.60	615.82
Total Comprehensive Income for the period	166.70	151.42	604.98
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.07	7.76	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Income from Operations	1,474.55	1,307.12	5,874.06
Profit Before Tax	216.16	84.01	704.23
Profit After Tax	201.87	130.54	666.48

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited  
Sd/-

Place: Vadodara  
Date: 9<sup>th</sup> May, 2024

Chirayu Amin  
Chairman and CEO

Note: The above results were also published yesterday. However, inadvertently, the details for the financial year ended 31<sup>st</sup> March, 2024 was missed out and hence this publication.







**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123  
 Regd. Office: Alembic Road, Vadodara - 390 003  
 Tel: 0265-6637300  
 Email: apl.investors@alembic.co.in  
 Website: www.alembicpharmaceuticals.com

**Extract of statement of consolidated audited financial results for the quarter and financial year ended 31<sup>st</sup> March, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Total Income from Operations	1,516.98	1,406.45	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	182.85	116.17	631.83
Net Profit for the period after tax attributable to shareholders of the Company (after Exceptional and/ or Extraordinary items)	178.21	152.60	615.82
Total Comprehensive Income for the period	166.70	151.42	604.98
Equity Share Capital	39.31	39.31	39.31
Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted	9.07	7.76	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.03.2024	31.03.2023	31.03.2024
	Audited	Audited	Audited
Income from Operations	1,474.55	1,307.12	5,874.06
Profit Before Tax	216.16	84.01	704.23
Profit After Tax	201.87	130.54	666.48

2. The above is an extract of the detailed format of the audited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited

Place: Vadodara  
 Date: 9<sup>th</sup> May, 2024

Sd/-  
 Chirayu Amin  
 Chairman and CEO

Note: The above results were also published yesterday. However, inadvertently, the details for the financial year ended 31<sup>st</sup> March, 2024 was missed out and hence this publication.